Skip to main content
. 2022 Mar 24;34(2):144–160. doi: 10.5021/ad.2022.34.2.144

Table 1. Summary of the patients enrolled in this study.

Patient no. Sex/age (yr) Diagnosis Injection site NRS score for control site NRS score for cooling site Reduction of NRS score Adverse event
1 M/37 Vitiligo Finger 10 5 5 None
2 M/66 Nail dystrophy Proximal nailfold 7 4 3 None
3 F/71 Nail dystrophy Proximal nailfold 10 6 4 None
4 F/65 Vitiligo Dorsum of hand 8 4 4 None
5 F/57 Nail dystrophy Proximal nailfold 5 3 2 None
6 F/53 Vitiligo Dorsum of hand 9 6 3 None
7 M/61 Prurigo nodularis Dorsum of hand 6 2 4 None
8 M/38 Nail dystrophy Proximal nailfold 5 2 3 None
9 F/55 Nail dystrophy Proximal nailfold 10 3 7 None
10 F/61 Nail psoriasis Proximal nailfold 10 2 8 None
11 F/49 Nail dystrophy Proximal nailfold 3 0 3 Burning sensation
12 M/43 Vitiligo Finger 8 5 3 None
13 F/47 Nail dystrophy Proximal nailfold 8 3 5 None
14 F/29 Nail psoriasis Proximal nailfold 5 3 2 None
15 F/33 Vitiligo Finger 6 4 2 None
16 F/67 Vitiligo Dorsum of hand 3 2 1 None
17 M/69 Prurigo nodularis Dorsum of hand 7 5 2 None
18 F/55 Vitiligo Dorsum of hand 7 5 2 None
19 F/67 Vitiligo Dorsum of foot 5 1 4 None
20 F/60 Nail dystrophy Proximal nailfold 5 2 3 None
21 F/66 Nail dystrophy Proximal nailfold 8 4 4 Burning sensation

M: male, F: female, NRS: numeric rating scale.